Immune-mediated myelitis following hepatitis B vaccination

Autoimmunity Reviews

Volumn 12, Issue 2, 2012, Pages 144-149

  Stubgen, Joerg Patrick ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Autoimmunity; Hepatitis B vaccine; Myelitis; Post vaccination

Indexed keywords

CORTICOSTEROID; DIPHTHERIA TETANUS TOXOID; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN; RECOMBINANT HEPATITIS B VACCINE;

B LYMPHOCYTE; CORTICOSTEROID THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE MEDIATED MYELITIS; INNATE IMMUNITY; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VACCINATION;

AUTOIMMUNITY; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; MYELITIS; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; VACCINATION;

EID: 84870255965     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.03.008     Document Type: Review

References (97)

1. Frohman E.M., Wingerchuk D.M. Transverse myelitis. N Engl J Med 2010, 263:564-572.
2. De Seze J., Stojkovic T., Breteau G., Lucas C., Michon-Pasturel U., Gauvrit J.Y., et al. Acute myelopathies: clinical, laboratory and outcome profiles in 79 cases. Brain 2001, 124:1509-1521.
3. De Seze J., Lanctin C., Lebrun C., Malikova I., Papeix C., Wiertlewski S., et al. Idiopathic acute transverse myelitis: application of recent diagnostic criteria. Neurology 2005, 65:1950-1953.
4. Berman M., Feldman S., Alter M., Zilber N., Kahana E. Acute transverse myelitis: incidence and etiologic considerations. Neurology 1982, 31:966-971.
5. Christensen P.B., Wermuth L., Hinge H.H., Bomers K. Clinical course and long-term prognosis of acute transverse myelopathy. Acta Neurol Scand 1990, 81:431-435.
6. Jeffrey D.R., Mandler R.N., Davis L.E. Transverse myelitis. Retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events. Arch Neurol 1993, 50:532-535.
7. Bhat A., Naguwa S., Cheema G., Gershwin M.E. The epidemiology of transverse myelitis. Autoimmun Rev 2010, 9:A395-A399.
8. Maldonaldo Y.A. Current controversies in vaccination. Vaccine 2002, 288:3155-3158.
9. Chen R.T., Pless R., DeStefano F. Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 2001, 16:309-318.
10. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005, 23:3876-3886.
11. Stratton K.R., Howe C.J., Johnston R.B. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994, 271:1602-1605.
12. Salemi S., D'Amelio R. Could autoimmunity be induced by vaccination?. Int Rev Immunol 2010, 29:247-249.
13. Shoenfeld Y., Aron-Maor A. Vaccination and autoimmunity-vaccinosis: a dangerous liaison?. J Autoimmun 2000, 14:1-10.
14. Agmon-Levin N., Kivity S., Szyper-Kravitz M., Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. Lupus 2009, 18:1198-1204.
15. Centers for Disease Control, Prevention Protection against viral hepatitis. Recommendations of the immunization practices advisory committee (ACIP). MMWR 1990, 39:1-26.
16. Centers for Disease Control and Prevention Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the immunization practices advisory committee (ACIP). MMWR 1991, 40:1-19.
17. Wasley A., Grytdal S., Gallagher K. Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ 2008, 57:1-24.
18. Francis D.P., Favero M.S., Maynard J.E. Transmission of hepatitis B virus. Semin Liver Dis 1981, 1:27-32.
19. McMahon B.J., Helminiak C., Wainwright R.B., Bulkow L., Trimble B.A., Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons. Am J Med 1992, 92:254-256.
20. Liang T.J. Hepatitis B: the virus and disease. Hepatology 2009, 49(Suppl.):S13-S21.
21. Lee W.M. Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
22. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2001, 34:1225-1241.
23. Geier M.R., Geier D.A., Zahalsky A.C. A review of hepatitis B vaccination. Expert Opin Drug Saf 2003, 2:113-122.
24. Tron F., Degos F., Bréchot C., Couroucé A.M., Goudeau A., Marie F.N., et al. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S2 and preS2 sequences. J Infect Dis 1989, 160:199-204.
25. Da Villa G., Picciottoc L., Elia S., Peluso F., Montanaro F., Maisto T. Hepatitis B vaccination: universal vaccination in newborn babies and children at 12years of age versus high risk groups. A comparison in the field. Vaccine 1995, 13:1240-1242.
26. Shouval D. Hepatitis B vaccines. J Hepatol 2003, 39(Suppl. 1):S70-S76.
27. Geier D.A., Geier M.R. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 2005, 38:295-301.
28. Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf 2003, 2:225-231.
29. Heijstek M.W., Ott de Bruin L.M., Borrow R., van der Klis F., Koné-Paul I., Fasth A., et al. Vaccination in paediatric patients with auto-immune rheumatic disease: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev 2011, 11:112-122.
30. Lobermann M., Borso D., Hilgendorf I., Fritzsche C., Zettl U.K., Reisinger E.C. Immunization in the adult immunocompromised host. Autoimmun Rev 2012, 11:212-218.
31. Shoenfeld Y., Jica C. Cholera vaccines: not live. Autoimmun Rev 2011, 11:157.
32. Bijl M., Agmon-Levin N., Dayer J.M., Israeli E., Gatto M., Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev Oct. 22 2011, [Epub ahead of print].
33. Van Assen S., Elkayam O., Agmon-Levin N., Cervera R., Dougados M., Emery P., et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature of the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. Autoimmun Rev 2011, 10:341-352.
34. Geier M.R., Geier D.A. Hepatitis B vaccine safety. Ann Pharmacother 2002, 36:370-374.
35. Geier M.R., Geier D.A. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol 2004, 22:749-755.
36. Hajdu S.D., Agmon-Levin N., Shoenfeld Y. Silicone and autoimmunity. Eur J Clin Invest 2011, 41:203-211.
37. Vera-Lastra O., Medina G., Del Pilar Cruz-Dominguez M., Ramirez P., Gayosso-Rivera J.A., Anduaga-Dominguez H., et al. Human adjuvant disease induced by foreign substance: a new model of ASIA (Shoenfeld's syndrome). Lupus 2012, 21:128-135.
38. Shoenfeld Y., Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36:4-8.
39. Agmon-Levin N., Hughes G.R.V., Shoenfeld Y. The spectrum of ASIA: 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants'. Lupus 2012, 21:118-120.
40. Zafrir Y., Agmon-Levin N., Paz Z., Shilton T., Shoenfeld Y. Autoimmunity following hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases. Lupus 2012, 21:146-152.
41. Mahassin F., Algayres J.P., Valmary J., Bili H., Coutant G., Bequet D., et al. Acute myelitis after vaccination against hepatitis B. Presse Med 1993, 22:1997-1998.
42. Trevisani F., Gattinara G.C., Caraceni P., Bernardi M., Albertoni F., D'Alessandro R., et al. Transverse myelitis following hepatitis B vaccination. J Hepatol 1993, 19:317-318.
43. Tartaglino L.M., Heiman-Patterson T., Friedman D.P., Flanders A.E. MR imaging in a case of postvaccination myelitis. AJNR 1995, 16:581-582.
44. Senejoux A., Roulot D., Belin C., Tsakaris L., Rautureau J., Coste T. Acute myelitis after immunization against hepatitis B with recombinant vaccine. Gastroenterol Clin Biol 1996, 20:401-402.
45. Song H.K., Kim H.C., Yun Y.H. Acute myelitis after hepatitis B vaccination. JKMS 1997, 12:249-251.
46. Renard J.L., Guillamo J.S., Ramirez J.M., Taillia H., Felten D., Buisson Y. Acute transverse cervical myelitis following hepatitis B vaccination. Evolution of anti-HBs antibodies. Presse Med 1999, 28:1290-1292.
47. Iñiguez C., Mauri J.A., Larrodé P., Lopez del Val J., Jerico I., Morales F. Acute transverse myelitis secondary to hepatitis B vaccination. Rev Neurol 2000, 31:430-432.
48. Karaali-Savrun F., Altintas A., Saip S., Siva A. Hepatitis B vaccine related-myelitis?. Eur J Neurol 2001, 8:711-715.
49. Fonseca L.F., Noce T.R., Texeira M.L., Texeira A.L., Lana-Peixoto M.A. Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection. Arq Neuropsiquiatr 2003, 61:265-268.
50. Isoda H., Ramsey R.G. MR imaging of acute transverse myelitis (myelopathy). Radiat Med 1998, 16:179-186.
51. Maillefert J.F., Sibilia J., Toussirot E., Vignon E., Eschard J.P., Lorcerie B., et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology 1999, 38:978-983.
52. DeStefano F., Mulloolly J.P., Okoro C.A., Chen T.R., Marcy S.M., Ward J.I., et al. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 2001, 108:E112.
53. Miller F.W., Hess E.V., Clauw D.J., Hertzman P.A., Pincus T., Silver R.M., et al. Approaches to identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000, 43:243-249.
54. Kinkaid O., Lipton H.L. Viral myelitis: an update. Curr Neurol Neurosci Rep 2006, 6:469-474.
55. Konstantinou D., Paschalis C., Maraziotis T., Dimopoulos P., Bassaris H., Skoutelis A. Two episodes of leukoencephalitis associated with recombinant hepatitis B vaccination in a single patient. Clin Infect Dis 2001, 33:1772-1773.
56. Vandenbroucke J.P. In defense of case reports and case series. Ann Intern Med 2001, 134:330-334.
57. Noordzij M., Dekker F.W., Zoccali C., Jager K.J. Study design in clinical research. Nephron Clin Pract 2009, 113:c218-c221.
58. DiPietro N.A. Methods in epidemiology: observational study design. Pharmacotherapy 2010, 30:973-984.
59. Paine R.S., Byers R.K. Transverse myelopathy in childhood. Am J Dis Child 1968, 85:151-163.
60. Dunne K., Hopkins I.J., Shield L.K. Acute transverse myelopathy in childhood. Dev Med Child Neurol 1986, 28:198-204.
61. Knebusch M., Strassburg H.M., Reiners K. Acute transverse myelitis in childhood: nine cases and review of the literature. Dev Med Child Neurol 1998, 40:631-639.
62. Defresne P., Hollenberg H., Husson B., Tabarki B., Landrieu P., Huault G., et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol 2003, 18:401-406.
63. Pidcock F.S., Krishnan C., Crawford T.O., Salorio C.F., Trovato M., Kerr D.A. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology 2007, 68:1474-1480.
64. Shaw F.E., Graham D.J., Guess H.A., Milstien J.B., Johnson J.M., Schatz G.C., et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years. Am J Epidemiol 1988, 127:337-352.
65. DeStefano F., Vestraten T., Jackson L.A., Okoro C.A., Benson P., Black S.B., et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003, 60:504-509.
66. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity - friends or foe?. Trends Immunol 2009, 30:409-414.
67. Olson J.K., Croxford J.L., Miller S.D. Virus-induced autoimmunity: potential role of viruses in initiation, perpetuation, and progression of T-cell-mediated autoimmune disease. Viral Immunol 2001, 14:227-250.
68. Tishler M., Shoenfeld Y. Vaccination may be associated with autoimmune diseases. Isr Med Assoc J 2004, 6:430-432.
69. Molina V., Shoenfeld Y. Infection, vaccines and environmental triggers of autoimmunity. Autoimmunity 2005, 38:235-245.
70. Maya R., Gershwin M.E., Shoenfeld Y. Hepatitis B virus (HBV) and autoimmune disease. Clin Rev Allergy Immunol 2008, 34:85-102.
71. Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol 2009, 5:648-652.
72. Olson J.K., Ercolini A.M., Miller S.D. A virus-induced molecular mimicry model of multiple sclerosis. Curr Top Microbiol Immunol 2005, 296:39-53.
73. Fujinami R.S., von Herrath M.G., Christen U., Whitton J.L. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006, 9:80-94.
74. Miller S.D., Vanderlugt C.L., Begolka W.S., Pao W., Yauch K.L., Neville Y., et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 1997, 3:1133-1136.
75. Katz-Levy Y., Neville K.L., Girvin A.M., Vanderlugt C.L., Pope J.G., Tan L.J., et al. Endogenous presentation of self-myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J Clin Invest 1999, 104:599-610.
76. McCoy L., Tsunoda I., Fujinami R.S. Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 2006, 39:9-19.
77. Roner S., Zinser E., Menges M., Wiethe C., Littmann L., Hanig J., et al. Minor role of bystander tolerance in fetal calf serum in peptide-specific dendritic cell vaccine model against autoimmunity: comparison with serum-free cultures. J Immunother 2008, 31:656-664.
78. Aichele P., Bachmann M.F., Hengartner H., Zinkernagel R.M. Immunopathology or organ-specific autoimmunity as a consequence of virus infection. Immunol Rev 1996, 152:21-45.
79. Barnaba V. Viruses, hidden self-epitopes and autoimmunity. Immunol Rev 1996, 152:47-66.
80. Nahill S.R., Welsh R.M. High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response. J Exp Med 1993, 177:710-715.
81. Brehm M.A., Markees T.G., Daniels K.A., Greiner D.L., Rossini A.A., Welsh R.M. Direct visualization of cross-reactive effector and memory allospecific CD8 T cells generated in response to viral infections. J Immunol 2003, 170:4077-4086.
82. Brocke S., Gaur A., Piercy C., Gautam A., Gijbels K., Fathman C.G., et al. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 1993, 365:642-644.
83. Kotzin B.L., Leung J., Kappler J., Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993, 54:99-166.
84. Ferri C., Zignego A. Relation between infection and autoimmunity in mixed cryoglobulinemia. Curr Opin Rheumatol 2000, 12:53-60.
85. Lidar M., Lipschitz N., Langevitz P., Shoenfeld Y. The infectious etiology of vasculitis. Autoimmunity 2009, 42:432-438.
86. Gilmore W., Correale J., Weiner L.P. Coronavirus induction of class I major histocompatibility complex expression in murine astrocytes is virus strain specific. J Exp Med 1994, 180:1013-1023.
87. Correale J., Li S., Weiner L.P., Gilmore W. Effect of persistent mouse hepatitis virus infection on MHC class I expression in murine astrocytes. J Neurosci Res 1995, 40:10-21.
88. Brickman C.M., Shoenfeld Y. The mosaic of autoimmunity. Scand J Clin Lab Invest Suppl 2001, 235:3-15.
89. Wucherpfennig K.W. Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 2001, 108:1097-1104.
90. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., et al. Adjuvant-enhanced antibody response in the absence of toll-like receptor signaling. Science 2006, 314:1936-1938.
91. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18:1217-1225.
92. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9:287-293.
93. Kool M., Soullié T., van Nimwegen M. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008, 205:869-882.
94. Schijns V.E. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000, 12:456-463.
95. Shoenfeld Y., Aharon-Maor A., Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clin Exp Rheumatol 2000, 18:181-184.
96. Meroni P.L. Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): old truths and new syndrome?. J Autoimmun 2011, 36:1-3.
97. Tomljenovic L., Shaw C.A. Aluminum vaccine adjuvants: are they safe?. Curr Med Chem 2011, 18:2630-2637.